BioVex raises another $30 million to fund Phase III OncoVEX programme
This article was originally published in Scrip
Executive Summary
BioVex has raised another $30 million to bring its series F total to $70 million. The first close of $40 million was announced in March this year. The proceeds will primarily be used to complete the ongoing pivotal Phase III study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialisation activities. The US-based biotech firm is aiming to submit a Biologics License Application filing in mid-2011.